OBJECTIVE: The objective of this study is to evaluate the safety and tolerability of inosine in patients with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives are to assess the effects of inosine administration on serum urate (UA) levels, the progression of neurologic disability, the cumulative number of new, active lesions on magnetic resonance imaging (MRI), and changes in serum levels for markers of inflammation. DESIGN: Oral administration of inosine was used to raise serum levels of the natural peroxynitrite scavenger UA in 16 patients with RRMS during a 1-year randomized, double-blind trial. OUTCOME MEASURES: The endpoints studied were relapse rate, disability assessed by the Kurtzke Expanded Disability Status Scale (EDSS), MRI, and analysis of serum levels of nitrotyrosine, and oxidative and pro-inflammatory makers. RESULTS: Increased serum UA levels correlated with a significant decrease in the number of gadolinium-enhanced lesions and improved EDSS. A number of MRI intensity-based parameters were altered by inosine treatment, in certain cases correlating with changes in serum UA levels. In a patient with low serum UA and high lesion activity, raising UA levels by inosine treatment decreased serum nitrotyrosine while increasing the ratio of Th2 to Th1 cytokines in circulating cells. The only side-effect correlated with inosine treatment was kidney stone formation in 4/16 subjects. CONCLUSIONS: These data suggest that the use of inosine to raise serum UA levels may have benefits for at least some MS patients. The effect of this treatment is likely to be a consequence of inactivation of peroxynitrite-dependent free radicals. Close monitoring of serum UA levels as well as other measures are required to avoid the potential development of kidney stones.
RCT Entities:
OBJECTIVE: The objective of this study is to evaluate the safety and tolerability of inosine in patients with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives are to assess the effects of inosine administration on serum urate (UA) levels, the progression of neurologic disability, the cumulative number of new, active lesions on magnetic resonance imaging (MRI), and changes in serum levels for markers of inflammation. DESIGN: Oral administration of inosine was used to raise serum levels of the natural peroxynitrite scavenger UA in 16 patients with RRMS during a 1-year randomized, double-blind trial. OUTCOME MEASURES: The endpoints studied were relapse rate, disability assessed by the Kurtzke Expanded Disability Status Scale (EDSS), MRI, and analysis of serum levels of nitrotyrosine, and oxidative and pro-inflammatory makers. RESULTS: Increased serum UA levels correlated with a significant decrease in the number of gadolinium-enhanced lesions and improved EDSS. A number of MRI intensity-based parameters were altered by inosine treatment, in certain cases correlating with changes in serum UA levels. In a patient with low serum UA and high lesion activity, raising UA levels by inosine treatment decreased serum nitrotyrosine while increasing the ratio of Th2 to Th1 cytokines in circulating cells. The only side-effect correlated with inosine treatment was kidney stone formation in 4/16 subjects. CONCLUSIONS: These data suggest that the use of inosine to raise serum UA levels may have benefits for at least some MS patients. The effect of this treatment is likely to be a consequence of inactivation of peroxynitrite-dependent free radicals. Close monitoring of serum UA levels as well as other measures are required to avoid the potential development of kidney stones.
Authors: Sergei V Spitsin; Gwen S Scott; Tatiana Mikheeva; Anna Zborek; Rhonda B Kean; Christine M Brimer; Hilary Koprowski; D Craig Hooper Journal: Free Radic Biol Med Date: 2002-11-15 Impact factor: 7.376
Authors: M H Williams; R B Kreider; D W Hunter; C T Somma; L M Shall; M L Woodhouse; L Rokitski Journal: Med Sci Sports Exerc Date: 1990-08 Impact factor: 5.411
Authors: H Ischiropoulos; L Zhu; J Chen; M Tsai; J C Martin; C D Smith; J S Beckman Journal: Arch Biochem Biophys Date: 1992-11-01 Impact factor: 4.013
Authors: Tara L Moore; Monica A Pessina; Seth P Finklestein; Ronald J Killiany; Bethany Bowley; Larry Benowitz; Douglas L Rosene Journal: Restor Neurol Neurosci Date: 2016-09-21 Impact factor: 2.406
Authors: Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio Journal: Neurology Date: 2019-09-04 Impact factor: 9.910
Authors: Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal Journal: Purinergic Signal Date: 2016-12-13 Impact factor: 3.765
Authors: Stella Célio Junqueira; Igor Dos Santos Coelho; Vicente Lieberknecht; Mauricio Peña Cunha; João B Calixto; Ana Lúcia S Rodrigues; Adair Roberto Soares Santos; Rafael Cypriano Dutra Journal: Mol Neurobiol Date: 2016-04-30 Impact factor: 5.590
Authors: Michael A Schwarzschild; Alberto Ascherio; M Flint Beal; Merit E Cudkowicz; Gary C Curhan; Joshua M Hare; D Craig Hooper; Karl D Kieburtz; Eric A Macklin; David Oakes; Alice Rudolph; Ira Shoulson; Marsha K Tennis; Alberto J Espay; Maureen Gartner; Albert Hung; Grace Bwala; Richard Lenehan; Elmyra Encarnacion; Melissa Ainslie; Richard Castillo; Daniel Togasaki; Gina Barles; Joseph H Friedman; Lisa Niles; Julie H Carter; Megan Murray; Christopher G Goetz; Jeana Jaglin; Anwar Ahmed; David S Russell; Candace Cotto; John L Goudreau; Doozie Russell; Sotirios Andreas Parashos; Patricia Ede; Marie H Saint-Hilaire; Cathi-Ann Thomas; Raymond James; Mark A Stacy; Julia Johnson; Lisa Gauger; J Antonelle de Marcaida; Sheila Thurlow; Stuart H Isaacson; Lisbeth Carvajal; Jayaraman Rao; Maureen Cook; Charlise Hope-Porche; Lauren McClurg; Daniela L Grasso; Robert Logan; Constance Orme; Tori Ross; Alicia F D Brocht; Radu Constantinescu; Saloni Sharma; Charles Venuto; Joseph Weber; Ken Eaton Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302